Analysis: Suven Life Sciences Limited

NSE:SUVEN Pharma - Formulators Market cap: ₹8.6K cr

Growth thesis

Suven Life Sciences operates as a drug-discovery entity post-2018 demerger, while Suven Pharmaceuticals handles CRAMS, specialty chemicals, and ANDAs. Key growth drivers include 15-20% revenue growth from CRAMS expansion (targeting ₹180-190 crore in FY21) and 40% EBITDA margins, alongside potential monetization of SUVN-G3031 (narcolepsy) by FY22 if Phase II trials succeed. However, SUVN-502 missed its Alzheimer’s endpoint, G3031 enrollment is at 20%, and cash covers 18 months, requiring partnerships or an IPO by FY22. CAPEX of ₹320 crore (OEL operational, Vizag expansion by 3Q FY21) supports capacity, but clinical delays and funding dependency remain critical risks.

Why is Suven Life Sciences Limited stock rising?

  • SUVN-502 secondary endpoints show positive implications for other indications; seeking agency guidance for a separate clinical trial within 45-60 days
  • SUVN-G3031 narcolepsy Phase II proof-of-concept trial enrollment at 20%; expected completion by March 2021
  • SUVN-D4010 indication finalization within two months; Phase II trial preparation underway
  • Pipeline of 14 molecules; earliest monetization opportunity in Q2/Q3 2021 based on positive outcome of SUVN-G3031
  • Funding plans for Suven Life Sciences include strategic partnerships, asset-based partnerships, or US IPO of Suven Neurosciences within 2.5 years

Research report

companyname: Suven Life Sciences Limited ticker: SUVEN sector: Biopharmaceuticals / Drug Discovery & Development Suven Life Sciences is a clinical-stage biopharmaceutical company based in Hyderabad, with a sole mission: discovering and developing new chemical entities (NCEs) for central nervous system (CNS) disorders. It was founded in 1989 by Venkateswarlu Jasti. For over two decades, the company has poured all its resources into building a pipeline of novel therapies for Alzheimer's disease, ...

Read the full report →

Catalysts

capex, new product segment, management upgrade

Growth guidance

15%-20% revenue growth for FY21

Management consistency

mixed

RS rating: 96 Stage: Stage 2

Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Suven Life Sciences Limited and 4,900+ companies.

Sign in
5-day free pass. No card required.
More in Pharma - Formulators